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Abstract  
Long-term use of opioid medication is associated with a host of negative effects on health and 
quality of life. Guidelines state that people with chronic pain taking high doses of opioids without 
benefit should be supported to discontinue them. Little research has investigated psychological 
processes associated with analgesic use and tapering. This study investigated (a) analgesic 
use pre- and post-participation in an interdisciplinary pain management programme and its 
relationship to functioning and (b) psychological processes associated with analgesic use. 
Opioid use was associated with poorer functioning at baseline. Participating in an 
interdisciplinary pain management programme was associated with reductions in opioid dose 
and number of classes of analgesics used. Reductions in analgesic use were associated with 
improvements in functioning. Psychological flexibility was associated with using higher doses of 
opioid medication and with using a greater number of classes of analgesics. Psychological 
flexibility appears relevant in explaining analgesic use. Future research could focus on targeting 
this process to improve tapering outcomes. 
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Introduction 
Chronic pain is common, affecting about one out of five people in the UK.1 A proportion of 
people with chronic pain derive limited benefit from medical treatments aiming to reduce pain, 
and treatments aiming specifically to improve functioning and quality of life (such as exercise 
and cognitive behavioural therapy; CBT) are recommended.2 Current NICE guidelines2 state 
opioids should not be offered for chronic low back pain, for example, especially not in the long-
term. The Royal College of Anaesthetists and British Pain Society identify a risk of harm 
associated with sustained doses above the equivalent of 120 milligrams (mg) total oral 
morphine equivalent dose (TOME) per 24 hours3 (TOME is also termed daily morphine 
equivalent dose; MED, and morphine milligrams equivalent; MME). If a patient with chronic pain 
is taking high doses of opioids and is not experiencing benefits, it is typically recommended that 
the opioids should be discontinued.3  
 
There has been a sizeable increase in the use of opioids for chronic pain in the UK4-6 and other 
countries, such as the United States.7 Zin et al.'s6 large UK cross-sectional study between 2000 
and 2010 showed the majority (87.8%, n=2,347,282) of strong opioid prescriptions were for non-
cancer pain. Continuation rates of opioid prescribing for chronic pain are high; over half of 
people prescribed 90 days of opioid therapy, excluding cancer pain / palliative care, over a six-
month period remain on opioids five years later.8,9 This is concerning given the mounting 
evidence that opioids are associated with a host of negative health outcomes when taken for 
long periods of time for chronic pain. Long-term opioid use for chronic pain has been associated 
with hyperalgesia.10 11 Higher doses are associated with poorer outcomes.12-15 These include 
increased risk of fractures,16 myocardial infarction,17 androgen deficiency / hypogonadism,18 
abuse,12,13,19,20 addiction,21,22 overdose23 and narcotic bowel syndrome.24 Unsurprisingly, there is 
an associated economic cost. In Hong et al.’s 25 retrospective cohort study of UK data, 
estimates of the 12-month costs associated with the treatment of chronic low back pain were at 
least double those of the matched controls without this diagnosis, representing a cost of £1.5 to 
£2.8 billion nationally. Most of the cost was associated with GP consultation time, but 19% was 
accounted for by analgesics alone.25 The NHS spend on opioids in the community in England in 
2016 was £292 million.26 Opioids for chronic pain are also associated with taking additional 
medications to prevent or minimise side-effects, more frequent healthcare visits and increased 
and more costly lengths of stay in hospital.3,25 There are of course also significant indirect costs 
associated with impaired physical, psychological, social and work functioning.3 
 
There are available interventions specifically to help people with chronic pain taper opioids.27-30 
However, evidence for these is unclear so far and a significant proportion of patients do not 
complete them successfully; drop-out rates of between 34% and 100% are reported.27 Several 
factors may interfere with successful tapering in people with chronic pain who are taking 
opioids. These include mental health problems, poor or avoidant coping styles and factors 
associated with risk of substance use.9,14,31-34 Frank et al.’s35 qualitative study identified barriers 
to tapering including fear of opioid withdrawal and pessimism about the availability of 
alternatives to opioids. McCracken et al.'s 36 survey of 220 patients with chronic pain showed 
over 80% endorsed the statement 'without medication my pain would be unbearable'. Of course, 
prescriber factors are relevant too.5 McCracken et al.37 found over 55% of GPs surveyed felt 
they had no alternatives than prescribing opioids for chronic pain.  
 
Interdisciplinary pain management programmes (PMPs) based on cognitive-behavioural 
principles are ‘the treatment of choice for people with persistent pain which adversely affects 
their quality of life’38 (p. 8) and there is good evidence for their efficacy.39,40 Such programmes 
usually include input from a nurse specialising in chronic pain, and sometimes information 
sessions from a consultant in pain medicine. Over the last 20 years, several (mostly 
uncontrolled) studies have indicated that participation on a PMP is associated with reduced 
healthcare consumption, including analgesic use 41-45 However, a recent meta-analysis46 of 
randomised controlled trials of psychological interventions for chronic pain did not find a 
significant effect for analgesic reduction (although it did find a significant reduction in other types 
of healthcare use). The authors urge cautious interpretation of this negative finding due to 
concerns about data quality and trial methodology and call for more study of this important 
outcome domain.46 Few studies have specifically examined which factors are associated with 
successful and unsuccessful opioid reduction and the specific processes that determine 
success. Of the seven RCTs identified by Pike46 that included changes in analgesic use as an 
outcome measure, only one 47 investigated the association between demographic variables and 
treatment gains (it did not find any significant associations) and none specifically investigated 
psychological factors as mediators of change.  
 
Current developments in PMPs include the psychological flexibility (PF) 48 model (the model 
underlying Acceptance and Commitment Therapy; ACT 49,50). PF can be defined as openness to 
experiencing pain and unwanted feelings, present-moment awareness, and values-oriented 
behaviour. 48 Psychological in-flexibility, on the other hand, is the opposite with respect to these 
qualities. It is reflected in behaviour that is guided by the urge to avoid unpleasant sensations, 
thoughts and emotions. The PF model is highly relevant to opioid reduction from a theoretical 
perspective and, because it clearly specifies relevant processes and mechanisms of change, 
the model offers a promising avenue for further refinement of treatment methods designed to 
help patients taper their analgesics.  
 
Long-term opioid use for chronic pain can be conceptualised as an understandable attempt to 
avoid pain and, when continued use is proving ineffective and is associated with interference in 
health and functioning, as a behaviour pattern that is a reflection of psychological inflexibility. 
Prospective data suggest that greater PF, including the component of openness to experiencing 
pain, is associated with less analgesic medication use.51 Participation on a PMP based on the 
PF model has been associated with reductions in analgesic use.52 Outside of chronic pain, this 
treatment approach has been used successfully to promote behavioural change in smoking 
cessation and alcohol and substance use.53-59  
 
In summary, long-term opioid use for chronic pain continues to be a significant and costly 
problem in the UK and elsewhere. There is little research on processes that may be relevant to 
facilitating tapering of analgesics, including opioids, in chronic pain. Methods based on the PF 
model that have been demonstrated to be effective in chronic pain are considered likely to 
facilitate opioid reduction by precisely targeting the same relevant underlying processes, and 
appear well designed to target the complexities that make tapering a challenge. Preliminary 
evidence in chronic pain and evidence from related fields supports this. 
 
The aim of the present study is to investigate clinical outcomes and therapeutic processes of 
change in relation changes in analgesic use in the context of an interdisciplinary PMP based on 
ACT.  More specifically we aim to examine: (a) differences on health-related variables between 
people who do and people who do not take opioid medication for chronic pain; (b) analgesic use 
pre- and post-treatment and its relationship to functioning (c) psychological processes 
associated with analgesic use at baseline and with changes in analgesic use.  
 
Method 
Participants  
Participants were recruited from 452 people with chronic pain referred to a speciality pain 
service in central London. All had been assessed by a psychologist and physiotherapist and 
deemed suitable to attend a four-week, residential, interdisciplinary, group-based PMP between 
August 2014 and April 2016. Approximately 55% of patients assessed by the service are offered 
a pain management programme, preparation for a programme (with the majority going on to 
begin a programme) or individual sessions within the service. The assessment included 
recording current medications to establish whether medicines were being taken as prescribed 
and that patients were able to self-administer them. When necessary, clinical nurse specialists 
provided advice to the assessing psychologist and physiotherapist (such as calculating 
approximate TOME dose / 24 hours). Inclusion criteria to attend the PMP included: pain 
duration of more than six months, presence of significant disability or distress from pain, and no 
plan for surgical or medical treatments that might impact the patient’s participation on the PMP. 
Exclusion criteria included the use of injectable analgesia, use of oral liquid opioids (as quantity 
taken had previously been found to be difficult to assess accurately) and use of high doses of 
opioids (above 300mg approximate TOME / 24 hours). If appropriate, patients who either met 
these exclusion criteria or whose medication use was associated with side-effects (e.g. 
drowsiness) that were likely to affect their ability to engage with the programme were offered the 
opportunity to work with a clinical nurse specialist prior to attending the programme. This might 
include, for example, transferring from liquid morphine to tablet-form, or reducing their TOME/ 
24 hours dose prior to attending. 
 
Participants ranged in age from 18 to 87 years old (mean 46.3 years, SD = 12.47), and the 
majority of participants defined their ethnicity as white (76.8%) and were unemployed because 
of pain (53.8%). 28.3% lived with their partner and child / children. The mean number of years 
of education was 13.49 (SD = 4.18) (see Table 1 for further details). 178 (40.9%) of participants 
reported their primary pain as lower back, and the median pain duration was 104 months 
(range: 4 to 703 months). The mean number of analgesic classes taken was 3.8 (SD = 1.6) and 
the mean approximate TOME / 24 hours dose was 65mg (SD = 97.7; median = 25mg, 
interquartile range = 94.5mg). 297 (68.3%) of the sample were taking opioid medication (see 
Table 2 for further details). 
 
[Insert Table 1] 
 
[Insert Table 2] 
 
Procedure  
Appropriate ethics and research and developmental committee approval was obtained prior to 
the study (North East Research Ethics Committee – South Central, REC reference 
12/SC/0451). Written consent was given by the patients for their data to be used for research. 
Of the 452 patients commencing treatment during the timeframe of the study, a total of 435 
patients consented to have their information used for research purposes. 
 
As part of standard clinical procedure, participants completed a set of self-report questionnaires 
including demographic questions (Table 1) and questions about their pain and medication use 
(Table 2), plus treatment-relevant process and outcome measures (further detailed below). 
These were completed on the first and last day of treatment, taking the majority of participants 
between 20 minutes and 60 minutes to complete. The questionnaires were checked at the time 
of completion to ensure minimal missing data. Physical performance measures were also 
obtained at these time points. 
 
On the first day and penultimate day of treatment, every participant met with the clinical nurse 
specialist individually. In this consultation, detailed lists of all the participants' current 
medications were recorded, including over-the-counter and herbal / alternative medications. The 
participants were asked specific questions about their analgesics, including dose, route, length 
of use, efficacy and presence of side-effects. In most cases, participants’ recollections of their 
medications were checked against the most recent medicines information from a GP summary, 
hospital discharge letter or community NHS care record. Occasionally, it was deemed 
appropriate to check against available packaging information, where the participant’s full name, 
date and dose was clearly documented.  
 
Outcome measures 
Medication use. Local guidelines were used to calculate approximate total oral morphine 
equivalent doses in 24 hours, recording separately an approximate oral immediate-release 
dose, modified-release dose and TOME. The local guidelines used to calculate these doses are 
in line with the approximate guides provided by the British National Formulary (BNF) and the 
resource Opioids Aware3 produced by the Faculty of Pain Medicine. The remaining analgesics 
were categorised by class, as per local guidelines in line with the BNF classification of 
medications. The categories are: Anticonvulsant; tricyclic anti-depressants; non-steroidal anti-
inflammatories, paracetamol, selective serotonin reuptake inhibitors/ serotonin noradrenalin 
reuptake inhibitors; hypnotics; anxiolytics / muscle relaxants; other.  
 
Pain intensity. Participants rated their pain intensity on average over the last week on a 
standard numeric rating scale from 0 (no pain) to 10 (extremely intense pain). 
 
Pain interference. The Brief Pain Inventory – Interference Scale (BPI-IS)60 is a seven item self-
report measure of pain interference with seven domains of daily activity that include: general 
activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. 
Participants report how much pain interfered with functioning over the past week on a scale of 0 
(does not interfere) to 10 (completely interferes). Higher scores indicate greater interference of 
pain. The BPI-IS has been well validated among patients with chronic pain.61 
 
Functioning. The Work and Social Adjustment Scale (WSAS)62 is a five item self-report measure 
assessing specific domains of functional impairment. Patients report how much their current 
condition impairs their ability to work, manage household activities, engage in social leisure 
activities, private leisure activities, and relationships with others on a scale of 0 (no impairment) 
to 8 (severe impairment). Higher total scores indicate greater functional impairment. The WSAS 
has been validated and is widely used in research in chronic health conditions.62 
 
Depression. The Patient Health Questionnaire (PHQ-9)63 is a measure of depression based on 
standard DSM-IV criteria. It includes nine items, measuring symptom frequency over the last 
two weeks on a scale of 0 (not at all) to 3 (nearly every day). Higher total scores indicate greater 
symptom severity. The PHQ-9 has been well validated among patients with chronic health 
conditions.63 Emotional functioning is a core outcome domain recommended by consensus 
guidelines.64 
 
Insomnia. The seven-item Insomnia Severity Index (ISI)65 is a screening measure of insomnia 
severity. Considering the last two weeks, participants are asked to rate the severity of difficulties 
falling asleep, staying asleep, sleep quality and its impact on daily functioning, as well as their 
concerns on a scale of 0 (not at all) to 4 (extremely). The summed items produce a total score, 
with more severe sleep problems indicated by higher scores. Total scores are categorised as 
not clinically significant (0-7), sub threshold (8-14), moderate insomnia (15-21) and severe 
insomnia (22-28).66 The ISI has been validated and shows good internal consistency in clinical 
samples65 including in this sample (Cronbach’s α = 0.86). 
 
Physical performance measures 
Participants were invited to complete three performance-based measures of physical 
functioning: 5-minute walk, 1 minute sit-to-stand, and 1-minute stair climb.67 The three 
measures have been validated among patients with chronic health conditions67,68 and have 
been used in outcome studies of interdisciplinary treatment programmes for chronic pain.69-73 
For the sake of brevity, only the 5-minute walk is reported on in this study. The 5-minute walk is 
a timed test of the number of metres a participant walks within five minutes up and down an 
empty 20 metre long corridor, with distance markers placed along the floor. Assessors were 
trained in standardised test administration and to give neutral responses with no 
encouragement or advice during testing. Participants were asked to perform the walk test 
without walking aids, such as crutches or sticks, if they were willing to do so. They were given 
permission to use the walls for support or to sit down as needed. Any stops against the wall or 
chair were recorded. Patients were informed of the time elapsed on each lap or at each minute 
if laps were very slow. This was not qualitative feedback but was intended to reflect real-life 
situations where patients may be likely to refer to time to determine their capacity to carry out 
activities. 
 
Treatment-relevant process measures 
The following measures capture different facets of the PF model: 
Acceptance. General psychological acceptance was measured using the seven-item measure, 
the Acceptance and Action Questionnaire (AAQ-II).74 This concept encompasses a willingness 
to experience difficult feelings and emotions, particularly when doing so enables one to pursue 
meaningful activities. Items are rated on a seven point scale from 1 (never true) to 7 (always 
true). In this study, higher scores reflect lower acceptance. Previous research has shown good 
internal consistency, temporal stability, and construct validity of the AAQ-II, including among 
patients with chronic pain.74,75 The AAQ showed excellent internal consistency in this sample 
(Cronbach’s α = 0.9). 
 
Pain acceptance. Acceptance of chronic pain was measured using the eight-item Chronic Pain 
Acceptance Questionnaire (CPAQ-8).76,77 This reflects degrees of engaging in normal daily 
activities with pain and refraining from ineffective avoidance or control strategies. Items are 
rated on a scale of 0 (never true) to 6 (always true) and higher total scores indicate greater 
acceptance of pain. The CPAQ-8 has been validated and shown to have good reliability in 
people with chronic pain.76. The CPAQ-8 showed acceptable internal consistency in this sample 
(Cronbach’s α = 0.7). 
 
Cognitive fusion. Cognitive fusion, the failure to experience distinctions between the content of 
thoughts and direct experience, was measured using the self-report seven item measure, the 
Cognitive Fusion Questionnaire (CFQ-7).78 Cognitive defusion in contrast, is similar to 
mindfulness processes in which participants see their thoughts as transient events which may 
or may not reflect reality, with the aim of reducing their impact. Participants are asked to rate 
how true a list of statements are for them using a scale of 1 (never true) to 7 (always true). 
When summed, higher total scores indicate greater cognitive fusion. The CFQ-7 has previously 
been validated among people with chronic pain79 and demonstrated excellent internal 
consistency in this sample (Cronbach’s α = 0.95). 
 
Decentering. Twelve-items of the Experiences Questionnaire (EQ)80,81 were used to assess 
decentering. This reflects one’s ability to observe thoughts and feelings as temporary, objective 
events in the mind and not necessarily true reflections of oneself or one’s circumstances. Each 
statement is rated on a scale of 1 (never) to 5 (always). Higher total scores suggest greater 
decentering. The EQ has been validated among people with chronic pain81. The decentering 
scale showed good internal consistency in this sample (Cronbach’s α = 0.9). 
 
Committed action. The Committed Action Questionnaire (CAQ-8)82,83 was used to measure 
persistence in flexible goal-oriented behaviour. The measure consists of eight items and asks 
participants to rate how true a list of statements are for them, using a scale of 0 (never true) to 6 
(always true). The item pool consists of four positively and four negatively phrased items. 
Negatively phrased items are reverse scored before the total score is calculated, with higher 
scores indicating greater committed action. The reliability and validity of the CAQ is supported 
by previous research in a chronic pain population82,83 and this good internal consistency was 
evident in this sample (Cronbach’s α = 0.8). 
 
Patient impression of change 
In addition, at the end of treatment, patients were asked to rate their impression of change 
overall and in the specific areas of physical and social functioning, work-related activities 
(including household work), mood, and pain using a scale of 1 (very much improved) to 7 (very 
much worse).84. Patient impression of change is recommended as an outcome measure by 
consensus guidelines.64 The factor structure and performance of this instrument has been 
examined in people with chronic pain upon completion of an interdisciplinary PMP, supporting 
its use.84 The following question was also included for the purposes of the present study and it 
is the sole one of the questions analysed here: ‘Compared to the start of treatment, on average, 
has your pain medication use: decreased, stayed the same, increased’.  
 
Description of treatment 
The PMP was delivered in a residential, interdisciplinary rehabilitation context by a team of 
psychologists, physiotherapists, occupational therapists, nurses and physicians. Treatment was 
provided in groups over four full days per week for four weeks. An ACT49,50 approach was used. 
This approach seeks to develop processes and skills relating to PF48: openness to experiencing 
pain and unwanted feelings, present-moment awareness, and values-oriented behaviour. Pain 
reduction was not an explicit focus of treatment. Consistent with BPS guidelines, treatment 
included 1) education sessions about medication to facilitate an informed choice about whether 
to reduce it, 2) individualised medication review, rationalisation and reduction under the 
guidance of the clinical nurse specialist, 3) the application of PF for overall improvement of daily 
functioning and to the goal of medication reduction (for example, making choices that are based 
on awareness and values, not habits and thoughts) and 4) liaison with the patient's GP and 
other agencies as appropriate. The PMP operates on an assumption of trust and negotiation of 
any medication reduction in a supportive environment. Individual reduction plans are developed 
in liaison with the patient, frequency of individual reviews are agreed and if required a written 
plan is provided. The clinical nurse specialist ensures that the multidisciplinary team are aware 
of the reduction plans at team meetings and the patients are monitored by the whole team, 
ensuring that the reduction process has minimal impact on patients’ engagement in the 
programme and to highlight when additional individual reviews are required. The clinical nurse 
specialist explains to the patient that they are in control of the reduction rate, with the aim to 
minimise the risk of withdrawal symptoms. Occasionally patients are unable to tolerate the 
reduction process whilst attending the programme. In these cases the clinical nurse specialist 
liaises with the General Practitioner and the individual support is provided following the 
programme. 
 
Statistical analyses 
Data analyses were conducted using SPSS version 22. Normality was assessed through 
examination of skewness and kurtosis values (between -2 and +2), and inspection of 
histograms and normal q-q plots. Independent-samples t-tests and chi-square were computed 
to compare participants who provided data at post-treatment with those who did not. For the 
pre- to post-treatment analyses, all of the paired differences were considered to be normally 
distributed except for TOME. Log natural transformation was used to address non-normality. 
Independent samples t-tests were used to compare people who did and people who did not 
take opioid medication on the study outcome and process variables. Means and standard 
deviations were computed for pre- and post-treatment scores and paired sample t-tests were 
then computed to determine the statistical significance of changes from pre- to post-treatment. 
The Bonferroni correction was used to adjust for multiple comparisons (p < 0.004). Within-
subjects effect sizes (Cohen’s d) were computed as the difference between pre- and post-
treatment means divided by the pooled standard deviation. Effect sizes were interpreted, 
according to Cohen’s85 guidelines, as small (>0.20), medium (>0.50), or large (>0.80). 
Participants making clinically significant changes in their analgesic use were defined as those 
whose raw change scores were greater than one half of a pooled standard deviation from their 
baseline score. A systematic review has shown that, across a number of chronic conditions, one 
half of a standard deviation reliably discriminates people who achieve a minimally important 
difference following treatment.86  
 
Pearson correlations were computed to examine the associations between the number of 
classes of medication at pre-treatment, and demographic, pain, outcome and process variables, 
as well as changes in these variables (using standardised change scores). Scatter plots for all 
variable pairs from the correlation analyses were examined for linearity. None of the variable 
pairs were considered to have significant nonlinear associations. Independent samples t-tests 
were performed to examine differences in medication use between genders and there were no 
significant differences on either medication variable. 
 
A series of hierarchical multiple linear regression were computed, first using pre-treatment 
scores and then residualised change scores, to examine the shared and unique contributions of 
the medication variables to measures of functioning. Pain intensity was controlled for in the first 
step of each analysis, followed by the medication variables in the final step of the regression 
equation. Only medication variables that were significantly correlated with the functioning 
variables in zero-order correlations were entered, simultaneously, into the equations as 
potential independent variables.  
 
Pairwise deletion was used to address missing values on study variables.  
 
  
 
 
Results 
 
Preliminary analyses 
35 people (8%) did not provide post-treatment data because they dropped out of treatment. A 
further 61 (14%) did not provide post-treatment data but did not drop-out of treatment (for 
example, they may have missed the session in which post-treatment measures were taken). 
Participants who provided data at post-treatment were compared with those who did not in 
terms of age, years of education, duration of pain, pain intensity during the last week, TOME 
and number of classes of medication, as well as all other outcome and all process variables. 
Those providing data at post-treatment had completed significantly more years of education 
t(428) = 3.690, p<.001. No significant differences were found on any of the other variables, 
including gender (chi-square test >.05). 
 
Compared to those not taking opioid medication at pre-treatment, those taking opioid 
medication scored higher for depression (t(373) = 2.881, p<.01), pain-related interference 
(t(375) = 2.787, p<.01) and sleep problems (t(374) = 3.403, p<.01). They walked less far (t(374) 
= - 2.635, p<.01) and scored lower on pain acceptance (t(372) = - 2.446, p<.05. The groups did 
not significantly differ on the other variables, including on average pain intensity over the last 
week. 
 
Treatment effects 
Mean values and standard deviations for all outcome and process measures at pre- and post-
treatment are presented in Table 3. Paired-samples t-tests and effect sizes were calculated to 
analyse the difference between pre- and post-treatment data for all measures (see Table 3). 
Statistically significant reductions were observed for all treatment outcomes and process 
measures including the variables of primary interest: log-TOME t(363) = 9.391, p<.004; total 
number of classes of medication t(362) = 11.619, p<.004. Immediate release opioids, non-
steroidal anti-inflammatories and paracetamol were the three classes of medication most 
frequently dropped during treatment, both in terms of raw numbers and when analysed by 
proportion of participants taking them at pre- and post-treatment.  
 
Large effect sizes were observed for depression and pain interference. Medium effect sizes 
were observed for average pain intensity, functioning (as measured by the WSAS), walking, 
pain acceptance and committed action. Small effect sizes were observed for TOME, number of 
classes of medication, insomnia, acceptance and decentering. The average effect size was .55 
and ranged from 0.17 for cognitive fusion to 1.11 for pain interference.   
 
[Insert Table 3] 
 
Clinical significance of treatment changes and patient impression of change 
The number of patients experiencing clinically significant reductions or increases in medication 
use is presented in Table 4. 12.4% made a clinically significant reduction in their TOME dose 
and 34.5% made a clinically significant reduction in the number of classes of medication they 
used.  
 
[Insert Table 4] 
 
At start of treatment, 71 people (16.3%) were taking doses of 120mg/ 24 hours TOME or 
greater, compared to 42 (9.7%) at end of treatment. This was a significant reduction (McNemar 
Test p<.001).  Of those taking doses of 120mg/ 24 hours TOME or greater at start of treatment, 
52.3% made a clinically significant reduction in TOME and 47.7% made a clinically significant 
reduction in number of classes of medication used.  
 
 
The following were the participants' responses to the question “Compared to the start of 
treatment, on average, has your pain medication use…: reduced [41.6%], stayed the same 
[36.8%], increased [8%]”, missing [13.6%]. 
 
Pre-treatment correlations between demographic factors and outcome variables, and 
medication use 
At pre-treatment, there were no significant correlations between medication use and age, 
education, pain duration or average pain intensity. Number of classes of medication and log-
TOME were significantly correlated with the following measures of functioning, in the expected 
directions: PHQ-9, BPI-IS, 5-minute walk and ISI (see Table 5). In addition, log-TOME was 
significantly correlated with the WSAS.  
 
[Insert Table 5] 
 
Pre-treatment correlations between process variables and medication use 
Number of classes of medication was significantly correlated with all measures of PF (as 
measured by the AAQ, CFQ, EQ, CPAQ and CAQ), in the expected directions. Log-TOME was 
significantly correlated with acceptance of pain (as measured by the CPAQ) only. See Table 5. 
 
Correlations between demographic factors and changes in outcome variables, and changes in 
medication use   
Demographic and pain variables did not correlate with changes in medication use. Changes in 
numbers of classes of medications were significantly correlated with changes in PHQ-9, BPI-IS, 
WSAS and ISI in the expected direction. Changes in TOME were correlated with changes the 
BPI-IS, WSAS and ISI in the expected direction. See Table 6.     
 
[Insert Table 6] 
 
Correlations between changes in process variables and changes in medication use 
Changes in number of classes of medication were correlated with changes in PF as measured 
by the AAQ and CFQ, in the expected direction. Changes in TOME did not correlate with 
changes in process variables. See Table 6.     
 
Regression analyses 
 
[Insert Table 7] 
 
Five multiple regression analyses using a hierarchical entry method were carried out to assess 
the contribution of TOME and medication classes to measures of patient functioning at baseline, 
after the contribution average pain intensity during the last week had been taken into account 
(see Table 7). The dependent variables in the analyses were PHQ-9, BPI-IS, WSAS, 5-minute 
walk and ISI. Only those variables that correlated significantly with the medication variables 
were used. Multicollinearity was not a concern (variance inflation factor; VIF <10 and tolerance 
statistic >0.1). The proportion of variance explained by the two medication variables together 
was significant for the PHQ-9, BPI-IS, WSAS, 5-minute walk and ISI, over and above average 
pain intensity. The proportion of variance explained by the two medication variables was small 
(1.2 – 4.6%). Number of medication classes uniquely predicted PHQ-9 and log-TOME / 24 
hours uniquely predicted the WSAS and 5-minute walk. 
 
[Insert Table 8] 
 
 
 
Regressions were carried out with changes in the standard clinical outcomes as the dependent 
variables, and changes in TOME and medication classes as the predictors (as well as changes 
in pain intensity) (see Table 8). Multicollinearity was not a concern (VIF <10 and tolerance 
statistic >0.1). The proportion of variance explained by changes in the medication variables was 
significant for changes in the PHQ-9, BPI-IS, WSAS and ISI, over and above changes in 
average pain intensity. The proportion of variance explained by changes in the two medication 
variables was small (1.5 – 3.0%). Changes in number of medication classes uniquely predicted 
changes in all four outcome variables. Changes in TOME / 24 hours did not uniquely predict 
changes in any outcome variables. 
 
Finally, independent t-tests were carried out to determine if opioid use at baseline was 
associated with the magnitude of the change scores on measures of functioning (PHQ-9, BPI-
IS, WSAS, 5-minute walk and ISI). However, the differences in changes on these measures 
between those using opioids or not, or those using above 120mg or below 120mg, were not 
significant.  
 
Discussion  
The purpose of this study was to investigate analgesic use amongst participants attending an 
interdisciplinary pain management programme. Specifically, it aimed to investigate general 
correlates of opioid use, changes in analgesic use during treatment and its relationship to 
functioning, and PF processes associated with medication use and changes in medication use.  
 
In summary, at baseline, people taking opioids showed higher rates of depression and poorer 
functioning than those not taking opioids. Number of classes of analgesics used and opioid 
dose correlated with depression, sleep problems, interference in functioning and walking. 
Higher opioid doses and using more classes of medication were correlated with poorer 
functioning. The two medication variables explained a significant proportion of variance in 
functioning (as measured by the PHQ-9, BPI-IS, WSAS, 5-minute walk and ISI). Participation on 
an interdisciplinary PMP was associated with reductions in number of classes of analgesics 
used and TOME dose. Changes in number of analgesic classes used predicted changes in 
functioning pre-post treatment. Higher PF was associated with using fewer analgesic classes 
and lower TOME dose at baseline, and pre-post treatment changes in some measures of PF 
correlated with changes in number of classes of medication.  
 
The higher rates of depression and interference and poorer functioning in the group using 
opioids, compared to those not using opioids is consistent with a large body of evidence 
showing long-term opioid use for chronic pain is associated with poorer health and 
functioning.10-23 Of course, it is not possible to infer causation from these results but they are 
further evidence of the psychosocial needs of this group of patients. These results indicate 
people using opioids are likely to require support as they taper their analgesics. 
 
Participation on an interdisciplinary PMP is associated with reductions in analgesic use, and this 
is correlated with improved functioning on key clinical outcomes, consistent with existing 
evidence.41-45 The improvements are independent of pain reduction. These results indicate that 
number of classes of medication used and TOME are both appropriate targets for treatment; if 
we can help patients to make reductions to these, functioning may improve. Nevertheless, the 
effect sizes for medication reduction are small and a sizeable proportion (46% or 71% according 
to how it is measured) do not make clinically significant reductions to their analgesics. This 
confirms that we need to continue to refine our treatment methods to help more people make 
more meaningful reductions.  
 
The results provide further evidence that PF is associated with analgesic use.51,52. Higher PF as 
measured by the AAQ, CFQ, EQ, CPAQ and CAQ is associated with using a smaller number of 
analgesic classes at baseline. This is consistent with the PF model in which medication use is 
conceptualised as pain avoidance behaviour. The relationship of PF with TOME dose was 
weaker, although TOME was correlated with the CPAQ. The weaker relationship is not 
surprising given that TOME is highly variable (as evidenced by the large standard deviation in 
this sample). How a particular dose affects a person is idiosyncratic and may depend on 
variables not captured in this data (such as length of time an individual has been taking opioid 
medication and variations in individual sensitivity to side-effects). Pre-post treatment changes in 
number of medication classes were correlated with the AAQ and CFQ. These results are 
preliminary and larger studies will be needed to investigate this further.  
 
The limitations of this study include the time-frame; some patients require longer than four-
weeks to make significant changes to their medication. The lack of follow-up means that those 
who make changes over longer periods would not be represented here, and also that it is not 
possible to ascertain whether the significant reductions in medication use identified at post-
treatment were sustained. For example, in a study of outcomes following interdisciplinary pain 
rehabilitation with weaning, 22% of participants followed up at 12 months reported resuming 
opioids post-programme.87 It is also possible that level of education influences medication 
changes; in the present study, those providing data at post-treatment had completed 
significantly more years of education than those who dropped out of treatment. As Song and 
Foell88 showed, opioid use tends to follow a fluctuating course and some people discontinue 
spontaneously so we cannot confirm that the changes were a result of participating in treatment. 
The sample size of this study was not sufficient to carry out sub-group analyses. For example, 
future research could specifically investigate people taking doses above 120mg TOME. 
Preliminary analysis here indicates more people in this group make clinically significant 
reductions to their analgesic use. Other limitations concern how medication use was measured 
in this study. As Pike46 notes, prescription data and patient self-report may differ as self-report  
is more likely to capture variation in adherence to prescribed use. This study triangulated patient 
self-report and prescription data in recognition of this an in an attempt to obtain the most 
accurate information possible. However, this method does not capture other relevant healthcare 
use, such as GP visits or pain procedures in secondary care. A related limitation is that no 
information was analysed about prescriber variables, which are of course just as relevant to 
analgesic use as patient variables.37 Finally, it should be acknowledged that the sample in this 
study referents a highly selected population, given that participants had been referred to, 
assessed as suitable for and were willing to engage in an intensive pain management 
programme. This means that the generalisability of the findings is unclear and remains to be 
demonstrated.  
 
In conclusion, this study provides further evidence that opioid use is a marker for greater 
difficulties in people with chronic pain, and that reductions in medication use may contribute to 
improvements in key clinical outcomes, including depression, pain interference and work and 
social functioning. Together with the results of previous studies, there is converging evidence 
that PF is significantly negatively associated with analgesic use in chronic pain. Future, larger 
studies could investigate this preliminary finding further and follow-up whether changes made 
during a pain management programme are sustained over time. This study confirms that we 
need to continue to refine our methods to better help those who do not successfully reduce their 
medication use despite intensive interdisciplinary input. The PF model offers an avenue for 
treatment development. By better targeting key processes of the PF model, we may improve 
outcomes. It is also important to note that not all patients are referred to, access or successfully 
complete an interdisciplinary pain management programme. Helpful developments might 
include other treatment formats that are accessible to a wider range of patients.  
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